Elekta Announces First Step in Integrating Treatment Planning with MOSAIQ Oncology Information System

Mon Jan 7, 2013 9:00am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


Elekta receives 510(k) clearance for MOSAIQ Evaluate, a toolset that integrates
treatment planning features into MOSAIQ OIS
ATLANTA,  Jan. 7, 2013  /PRNewswire/ -- As part of a process to completely
integrate the patient's electronic medical record (EMR) with treatment planning
activities, Elekta has introduced MOSAIQ Evaluate*, a toolset that unites plan
and dose review capabilities in a single software framework, MOSAIQ Oncology
Information System (OIS). Uniting MOSAIQ and powerful treatment planning review
capabilities streamlines planning activities inside the patient chart, reducing
patient wait times and delays and improving efficiency and productivity in the
department. Elekta recently received 510(k) clearance from the U.S. Food and
Drug Administration (FDA) for MOSAIQ Evaluate.

"The development of MOSAIQ Evaluate establishes a new standard of oncology
treatment planning management in a single software environment. Our belief is
that clinical decision-making is improved when the radiotherapy team can access
and review treatment and patient data from one source, MOSAIQ," says  Todd
Powell, Executive Vice President,  Elekta Software. "It's the first step in a
process in which we will steadily integrate advanced toolsets inside MOSAIQ,
ultimately creating an advanced, comprehensive treatment planning solution
inside the EMR."

With MOSAIQ Evaluate, the entire radiation oncology team can access and review
treatment plans and patient data from the patient's chart, streamlining the
radiotherapy workflow. It enables plan review from virtually any treatment
planning system and for any treatment modality, in addition to comparison of
multiple plans.  

To support the multidisciplinary team, MOSAIQ Evaluate offers specific benefits
for the radiation oncologist, the physicist and the dosimetrist. Radiation
oncologists and physicists will now be able to review plans at their MOSAIQ
workstation and view a "to-do" list of plans needing review. MOSAIQ Evaluate
also enables the physicist to identify approved plan information side-by-side
with all treatment fields, approve treatment fields directly from the Plan
Worklist, and view imported DRR's alongside the treatment plan. With MOSAIQ
Evaluate, dosimetrists will be able to use the Plan Worklist to identify
approved plans, triggering the next step in the workflow.  

To learn more, visit  www.elekta.com/evaluate.  

*MOSAIQ Evaluate is not available for sale or distribution in all markets.
Please contact the local Elekta representative for details.

For further information, please contact:
Johan Andersson Melbi, Director, Investor Relations,  Elekta AB
Tel: +46 702 100 451, email:  johan.anderssonmelbi@elekta.com  
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta 

Tel: +1 770-670-2447, email:  michelle.joiner@elekta.com 
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.  

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,400 employees globally. The
corporate headquarters is located in  Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker EKTAb. Website:  www.elekta.com.

SOURCE  Elekta
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.